ACP
EIGR

Acuta Capital Partners’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Acuta Capital Partners’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-9,750
Closed -$2.81M – 56
2020
Q2 		$2.81M Buy
+9,750
New +$2.87M 0.81% 36
2015
Q4 		– Sell
-1,822
Closed -$861K – 69
2015
Q3 		$861K Buy
+1,822
New +$966K 0.5% 47

Other funds holding EIGR

6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Acuta Capital Partners's EIGR Position: Q3 2020 in Review

Acuta Capital Partners sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2020, closing a stake of 9,750 shares — an estimated $2.81M sold.

Acuta Capital Partners first reported a position in EIGR in Q3 2015 and held it in 2 quarters. The position peaked at $2.81M in Q2 2020. 102 funds tracked by Wall St. Rank hold EIGR as of Q3 2020.

  • Acuta Capital Partners reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Acuta Capital Partners sold 9,750 Eiger BioPharmaceuticals, Inc. shares in Q3 2020, an estimated $2.81M.
  • Acuta Capital Partners first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2015 and held it in 2 quarters.
  • Acuta Capital Partners's Eiger BioPharmaceuticals, Inc. position peaked at $2.81M in Q2 2020.
  • 102 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2020.

Based on Acuta Capital Partners's 13F filing for Q3 2020, filed 16 Nov 2020.